E130309D02Rik Inhibitors
Integrator complex subunit 15 (Ints15) is a vital component of the integrator complex, a multiprotein assembly that plays a crucial role in eukaryotic RNA metabolism. The integrator complex is predominantly known for its involvement in the 3'-end processing of small nuclear RNAs (snRNAs) and other non-coding RNAs transcribed by RNA polymerase II. The intricate processing of these transcripts is fundamental for the formation of mature snRNAs, essential components of the spliceosome machinery responsible for pre-mRNA splicing. Ints15, positioned within this complex, contributes to the precise cleavage of the 3'-end of RNA polymerase II transcripts, ensuring the production of functional snRNAs that participate in various cellular processes, including mRNA splicing and other nuclear events.
To comprehend the potential mechanisms of inhibiting Ints15, it is crucial to understand its involvement in key cellular pathways. Inhibition strategies may be directed towards disrupting the processes associated with the integrator complex, influencing RNA polymerase II activity, or altering chromatin structure. Inhibitors targeting RNA polymerase II may impede the synthesis of precursor transcripts, impacting the substrates processed by Ints15 within the integrator complex. Similarly, modulation of chromatin accessibility through histone deacetylase inhibitors or bromodomain inhibitors can indirectly influence Ints15 by altering the transcriptional landscape, affecting the availability of RNA substrates for processing. Additionally, targeting topoisomerases or the spliceosome machinery may disrupt the upstream processes leading to the formation of transcripts processed by Ints15. Understanding the interconnected nature of these pathways provides insights into potential points of intervention for inhibiting Ints15 function and subsequently altering RNA processing dynamics within the cell. In conclusion, elucidating the intricate role of Ints15 in RNA metabolism and exploring potential inhibition strategies opens avenues for unraveling the complexities of gene expression regulation, contributing to a deeper understanding of cellular processes governed by the integrator complex.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
An RNA synthesis inhibitor targeting RNA polymerase II (RNAPII). Inhibition of RNAPII activity can impact the substrates for Ints15, disrupting the processing of small nuclear RNAs within the Integrator complex. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
A topoisomerase I inhibitor. Inhibition of topoisomerase I affects DNA topology, indirectly influencing Ints15 by altering the accessibility of DNA for transcription and the synthesis of RNA substrates for the Integrator complex. | ||||||
Spliceostatin A | 391611-36-2 | sc-507481 | 1 mg | $1800.00 | ||
A natural compound inhibiting spliceosome assembly. Disruption of the spliceosome can indirectly affect Ints15 by disrupting the splicing process and subsequently the substrates for the Integrator complex. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
An HDAC inhibitor impacting chromatin structure. Modulation of chromatin accessibility may indirectly influence Ints15 by altering the transcriptional landscape and the availability of RNA substrates for processing by the Integrator complex. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
A CDK inhibitor influencing the cell cycle and RNAPII activity. Indirect effects on Ints15 may occur through alterations in transcription rates and the availability of substrates for the Integrator complex. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
A DNA methyltransferase inhibitor. Inhibition of DNA methyltransferases may impact epigenetic regulation, influencing Ints15 expression by altering DNA methylation patterns and the availability of RNA substrates for the Integrator complex. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor affecting protein degradation. Indirect effects on Ints15 may occur by altering the stability of proteins involved in its regulation, impacting the cellular environment and substrates for the Integrator complex. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor regulating mRNA translation. Indirect effects on Ints15 may occur by altering the synthesis of proteins involved in RNA processing, affecting the substrates for the Integrator complex. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
A NF-κB inhibitor modulating transcriptional activity. Indirect effects on Ints15 may occur through alterations in NF-κB-regulated gene expression, impacting the cellular context and availability of RNA substrates processed by the Integrator complex. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
A topoisomerase II inhibitor affecting DNA topology. Indirect effects on Ints15 may occur by altering the accessibility of DNA for transcription and the synthesis of RNA substrates for the Integrator complex. | ||||||